

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-32609A
APPLICATION NO.
10/523,047
APPLICANT
LANE ET AL.
FILING DATE
FEBRUARY 2, 2005

Sheet 1 of 1

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/SP/	AA	6,391,553	5/02	Amouyel, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 95/16791	6/95	PGT			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

/Steven Pohnert/ (05/02/2007)

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-32609A
APPLICATION NO.
10/523,047
APPLICANT
LANE ET AL.
FILING DATE
FEBRUARY 2, 2005

Sheet 2 of 2

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Winblad, et al., "A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD", Neurology, Vol. 57, pp. 489-95 (2001)
DB	Farlow et al., "Apolipoprotein E genotype and gender influence response to tacrine therapy", Annals of the New York Academy of Sciences; Apolipoprotein E, pp. 101-110, (1996)
DC	Sjogren et al., "Tacrine and rate of progression in Alzheimer's disease: relation to ApoE allele genotype", Journal of Neural Transmission, Vol. 106, pp. 451-56, (2001)
DD	Aerssens et al., "ApoE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease," Dementia and Geriatric Cognitive Disorders, Vol. 12, pp. 69-77, (2001)
DE	Nobili et al., "Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors," Journal of Nuclear Medicine, Vol. 43, pp. 983-90, (2002)
DF	Database WPI, Derwent Publications Ltd., London, GB; An 2000-264443, XP002265851, Apolipoprotein E4-specific monoclonal antibody used for immunoassay of ApoE does not react with ApoE isoforms 2 and 3," (March 2000)
DG	Stefanova et al., "Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients." Neuroscience Letters, Ireland, Vol. 338, pp. 159-163, (2003)
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

/Steven Pohnert/ (05/02/2007)

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.